Alterity Therapeu…
AUAUDAlterity Therapeutics Ltd (US:PRNAF) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- alteritytherapeutics.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- MELBOURNE, Australia
- Izvršni direktor
- Dr. David A. Stamler M.D.
- Zaposleni
- 11
- Delnice v obtoku
- 217.51 mio. na dan 2026-06-30
- Prosto prenosljive delnice
- 171.39 mio.
- Tržna kapitalizacija
- 81.28 mio. AUD
- Notranje osebe
- 7.91%
- Institucionalni vlagatelji
- 17.98%
- Panoga (SIC)
- Pharmaceutical Preparations
Opis
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Dividende
Ni bilo najdenih izplačil dividend (preverjeno 09.10.2026). Podjetje verjetno ne izplačuje dividend.
Novice ta teden
Novic s spletnega mesta podjetja še ni.
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| Meltzer (Brian Derek) (F… | ≈49.36% | 9.42 mio. | 2025-11-21 |
| Gozlan (Lawrence) (Direc… | ≈23.83% | 4.55 mio. | 2025-04-07 |
| Marks (Peter Vincent) (I… | ≈1.19% | 227 704 | 2026-08-31 |
| Twin Lakes Capital Manag… | 0.73% | 139 258 | 2026-06-30 |
| Morgan Stanley | 0.33% | 63 065 | 2026-06-30 |
| Greenleaf Trust | 0.32% | 62 000 | 2026-06-30 |
| HB Wealth Management, LL… | 0.31% | 58 460 | 2026-06-30 |
| Citadel Advisors Llc | 0.2% | 37 597 | 2026-06-30 |
| Kempler (Geoffrey Paul)… | ≈0.16% | 30 000 | 2025-11-21 |
| HRT Financial LP | 0.09% | 17 292 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.05% | 10 239 | 2026-06-30 |
| Gamma Investing LLC | 0.01% | 2 309 | 2026-06-30 |
| Rhumbline Advisers | 0.01% | 2 009 | 2026-06-30 |
| Acadian Asset Management… | 0.01% | 1 863 | 2026-06-30 |
| Fidelity Concord Street… | 0.01% | 1 155 | 2026-05-31 |
| Stamler (David) (Chief E… | — | 91.69 mio. | 2025-11-21 |
